Personal data
Survey Questions
Centrum Badań Klinicznych PI-House sp. z o. o.
NIP: 9571059089 | EU VAT ID: PL9571059089
REGON: 221506777 | KRS: 0000394618
Share capital: PLN 60,000
Entry number in the Register of
Health Care Providers: 000000154510
Study title: Open-label long-term safety study of esketamine nasal spray dose extension in treatment-resistant depression
Therapeutic area: Treatment-resistant depressive disorder
Phase: III
Start Date: June 9, 2016
End date: December 31, 2022
Status: Not recruiting
Sponsor Name: Janssen Research & Development, LLC
Study title: Long-term, multicentre, randomized, double-blind, controlled, parallel group study of the safety and efficacy of Lemborekxant in people with insomnia disorders
Therapeutic area: Disorder of insomnia
Phase: III
Start Date: November 15, 2016
End date: January 8, 2019
Status: Not recruiting
Sponsor Name: Eisai Inc.
Study title: Adaptive, multicentre, prospective, randomized, double-blind, placebo-controlled phase IIb / III study of the safety and efficacy of NaBen® (DAAO inhibitor) as an additional treatment for schizophrenia in adults
Therapeutic area: schizophrenia
Phase: IIb / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx
Study title: Adaptive Phase II / III study, two-part, double-blind, randomized, placebo-controlled, dose-titled multicenter study of the safety and efficacy of NaBen® as add-on therapy with clozapine for the treatment of symptoms of refractory schizophrenia in adults
Therapeutic area: schizophrenia
Phase: II / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx
English (UK) 
Polski